科研成果详情

题名Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction
作者
发表日期2024-06-15
发表期刊Journal of pharmaceutical and biomedical analysis   影响因子和分区
语种英语
原始文献类型Journal Article
关键词Fluconazole Iguratimod M2 Pharmacokinetics Rat UPLC-MS/MS
摘要This aim of the work was to establish an acceptable sensitive assay based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) for quantitatively analyzing the plasma concentrations of iguratimod (IGR) and its metabolite M2 in rats, and to further investigate the effect of fluconazole on the pharmacokinetics of IGR and M2. The mobile phase consisted of acetonitrile and water with 0.1% formic acid, was used to separate IGR, M2 and internal standard (IS) fedratinib on a UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with the flow rate of 0.4 mL/min. Positive ion mode and multiple reaction monitoring (MRM) were used to construct the quantitative analysis. The calibration standard of IGR and M2 covered 2-10000 and 1-1000 ng/mL respectively, with the lower limit of quantification (LLOQ) as 2 ng/mL and 1 ng/mL respectively. In addition, selectivity, recovery, accuracy, precision, matrix effect and stability of the method validation program were well accepted in this work. Subsequently, this approach was used to assess the effect of fluconazole on the pharmacokinetics of IGR and M2 in rats. In the presence of 20 mg/kg fluconazole (experimental group), we found the main pharmacokinetic parameters were significantly altered when compared with 2.5 mg/kg IGR alone (control group). Among them, AUC(0-∞) and Cmax of IGR in the experimental group was 1.43 and 1.08 times higher than that of the control group, respectively. Moreover, we also found that the other main pharmacokinetic parameters of M2 had no significant changes, except t1/2z and Tmax. In conclusion, fluconazole significantly altered the main pharmacokinetics of IGR and M2 in rats. It implys that we should pay more attention to the adverse reaction of IGR when the concomitant use of fluconazole and IGR occur in the future clinical practice
出版者ELSEVIER
ISSN0731-7085
EISSN1873-264X
卷号243
DOI10.1016/j.jpba.2024.116079
页数6
WOS类目Chemistry, Analytical ; Pharmacology & Pharmacy
WOS研究方向Chemistry ; Pharmacology & Pharmacy
WOS记录号WOS:001206348900001
收录类别PUBMED ; SCOPUS ; SCIE
URL查看原文
PubMed ID38471255
SCOPUSEID2-s2.0-85187497034
通讯作者地址[Xu, Ren-ai]The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,China
Scopus学科分类Analytical Chemistry;Pharmaceutical Science;Drug Discovery;Spectroscopy;Clinical Biochemistry
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/210259
专题附属第一医院
其他_附属第三医院(瑞安市人民医院)
通讯作者Xu, Ren-ai
作者单位
1.The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,China;
2.The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital),The Third Clinical Institute Affiliated to Wenzhou Medical University,Zhejiang,China
第一作者单位附属第一医院;  第一临床医学院(信息与工程学院)、附属第一医院
通讯作者单位附属第一医院;  第一临床医学院(信息与工程学院)、附属第一医院
第一作者的第一单位附属第一医院
推荐引用方式
GB/T 7714
Shi, Lu,Hu, Jinyu,Wu, Hualu,et al. Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction[J]. Journal of pharmaceutical and biomedical analysis,2024,243.
APA Shi, Lu., Hu, Jinyu., Wu, Hualu., Shen, Yuxin., Chen, Xiaohai., ... & Tang, Congrong. (2024). Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction. Journal of pharmaceutical and biomedical analysis, 243.
MLA Shi, Lu,et al."Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction".Journal of pharmaceutical and biomedical analysis 243(2024).

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Shi, Lu]的文章
[Hu, Jinyu]的文章
[Wu, Hualu]的文章
百度学术
百度学术中相似的文章
[Shi, Lu]的文章
[Hu, Jinyu]的文章
[Wu, Hualu]的文章
必应学术
必应学术中相似的文章
[Shi, Lu]的文章
[Hu, Jinyu]的文章
[Wu, Hualu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。